Trial · NCT00905424
Outcomes18
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 18 of 18
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF) | Augmentation Baseline, 6 weeks | Primary Efficacy Analysis Set defined as all non-remitters (MADRS total score greater than 10 at augmentation baseline) who take at least 1 dose of randomized augmentation treatment and have at least 1 primary efficacy measurement after randomization. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Non-Remitters in the Hamilton Depression Scale (HAM-D) Total Score at Week 6 - LOCF | Augmentation Baseline, 6 weeks | Primary Efficacy Analysis Set | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Non-Remitters in the Sheehan Disability Scale (SDS) Total Score at Week 6 | Augmentation Baseline, 6 weeks | Primary Efficacy Analysis Set | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Non-Remitters With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 6 - LOCF | 6 weeks | Primary Efficacy Analysis Set | Percent of Participants | NUMBER |
| SECONDARY | Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Augmentation Baseline | Augmentation baseline | Primary Efficacy Analysis Set | Percent of participants | NUMBER |
| SECONDARY | Assessment in Non-Remitters of Clinical Global Impression-Severity of Illness (CGI-S) at Week 6 | 6 weeks | Primary Efficacy Analysis Set | Percent of participants | NUMBER |
| SECONDARY | Change From Augmentation Baseline for Non-Remitters in the Behavior Rating Inventory of Executive Function - Adult Version (BRIEF-A) Scale Total Score at Week 6 | Augmentation Baseline and 6 weeks | Primary Efficacy Analysis Set | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Non-Remitters in the Multidimensional Assessment of Fatigue (MAF) Scale Total Score at Week 6 | Augmentation Baseline and 6 weeks | Primary Efficacy Analysis Set | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Non-Remitters in the Quick Inventory of Depressive Symptomatology - Self-Report (QIDS-SR) Scale Total Score at Week 6 | Augmentation Baseline and 6 weeks | Primary Efficacy Analysis Set | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Remitters in MADRS Total Score at Week 6 - LOCF | Augmentation Baseline and 6 weeks | Full Analysis Set (FAS) defined as all subjects who take at least 1 dose of randomized augmentation treatment and have at least 1 primary efficacy measurement after randomization. | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Remitters in the HAM-D Total Score at Week 6 - LOCF | Augmentation Baseline and 6 weeks | FAS | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Remitters in the SDS Total Score at Week 6 | Augmentation Baseline and 6 weeks | FAS | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Percentage of Remitters With Improvement on CGI-I at Week 6 - LOCF | 6 weeks | FAS | Percent of participants | NUMBER |
| SECONDARY | Assessment in Remitters of CGI-S at Augmentation Baseline | Augmentation Baseline | FAS | Percent of participants | NUMBER |
| SECONDARY | Assessment in Remitters of CGI-S at Week 6 | 6 weeks | FAS | Percent of participants | NUMBER |
| SECONDARY | Change From Augmentation Baseline for Remitters in the BRIEF-A Scale Total Score at Week 6 | Augmentation baseline and 6 weeks | FAS | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Remitters in the MAF Scale Total Score at Week 6 | Augmentation baseline and 6 weeks | FAS | Units on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Augmentation Baseline for Remitters in the QIDS-SR Scale Total Score at Week 6 | Augmentation baseline and 6 weeks | FAS | Units on a scale | LEAST_SQUARES_MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00905424/outcomes